Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. Its lead product candidate, ZN-c5, is an oral selective estrogen receptor degrader (SERD) for the treatment of estrogen receptor positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced or metastatic breast cancer. The company was founded by Kevin D. Bunker on December 23, 2014 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. The company was founded by Kevin D. Bunker and Cam Gallagher on December 23, 2014 and is headquartered in San Diego, CA.

NEW YORK, NY / ACCESSWIRE / August 2, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Zentalis Pharmaceuticals, Inc. ("Zentalis") (NASDAQ:ZNTL) concerning possible violations of federal securities laws. Zentalis announced on June 18, 2024, that "the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on the following studies of azenosertib: the Phase 1 ZN-c3-001 dose-escalation study in solid tumors, the Phase 2 ZN-c3-005 (DENALI) study in platinum-resistant ovarian cancer (PROC) and the Phase 2 ZN-c3-004 (TETON) study in uterine serous carcinoma (USC).

Did Zentalis Pharmaceuticals, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - ZNTL

LOS ANGELES , Aug. 2, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zentalis Pharmaceuticals, Inc. ("Zentalis" or "the Company") (NASDAQ: ZNTL) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

ZNTL Investors Have Opportunity to Join Zentalis Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm

NEW YORK, NY / ACCESSWIRE / August 1, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Zentalis Pharmaceuticals, Inc. ("Zentalis") (NASDAQ:ZNTL) concerning possible violations of federal securities laws. Zentalis announced on June 18, 2024, that "the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on the following studies of azenosertib: the Phase 1 ZN-c3-001 dose-escalation study in solid tumors, the Phase 2 ZN-c3-005 (DENALI) study in platinum-resistant ovarian cancer (PROC) and the Phase 2 ZN-c3-004 (TETON) study in uterine serous carcinoma (USC).

ATTENTION Zentalis Pharmaceuticals, Inc. Investors: You May Have Been Affected by Fraud - Contact Levi & Korsinsky to Discuss Your Rights

Zentalis' (ZNTL) three studies evaluating azenosertib for three different cancer indications face the FDA's partial clinical hold following the death of two patients.

Zentalis (ZNTL) Tanks After FDA Puts 3 Cancer Studies on Hold

ATLANTA, June 18, 2024 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Zentalis Pharmaceuticals, Inc. (“Zentalis” or the “Company”) (NASDAQ: ZNTL) complied with federal securities laws. On June 18, 2024, Zentalis announced that “the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on the following studies of azenosertib: the Phase 1 ZN-c3-001 dose-escalation study in solid tumors, the Phase 2 ZN-c3-005 (DENALI) study in platinum-resistant ovarian cancer (PROC) and the Phase 2 ZN-c3-004 (TETON) study in uterine serous carcinoma (USC).” Following this news, the price of the Company's stock dropped.

Investigation Into Zentalis Pharmaceuticals, Inc. (ZNTL) Announced byHolzer & Holzer, LLC

Tuesday, Zentalis Pharmaceuticals Inc ZNTL announced that the FDA has placed a partial clinical hold on the following studies of azenosertib:

Why Is Small-Cap Cancer-Focused Zentalis Pharma Stock Trading Lower On Tuesday?

Zentalis Pharmaceuticals said on Tuesday the U.S. Food and Drug Administration has placed a partial clinical hold on three studies testing its cancer drug, following the death of two trial participants.

US FDA puts partial clinical hold on Zentalis' cancer drug studies; shares drop

FDA has placed a partial clinical hold on ZN-c3-001, DENALI and TETON monotherapy  studies of azenosertib Monotherapy data to be presented in the second half of 2024 Conference call to be held today, June 18, 8:00 am ET SAN DIEGO, June 18, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on the following studies of azenosertib: the Phase 1 ZN-c3-001 dose-escalation study in solid tumors, the Phase 2 ZN-c3-005 (DENALI) study in platinum-resistant ovarian cancer (PROC) and the Phase 2 ZN-c3-004 (TETON) study in uterine serous carcinoma (USC). This action follows two recent deaths due to presumed sepsis in the DENALI study.

Zentalis Pharmaceuticals Provides Update on Azenosertib Clinical Development Program

NEW YORK and SAN DIEGO, May 30, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that Zentalis management is scheduled to participate in a fireside chat at the upcoming Jefferies Global Healthcare Conference on June 5, 2024, at 4:00 p.m. ET.

Zentalis Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

NEW YORK and SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced the appointment of Luke Walker, M.D., to its Board of Directors. Dr. Walker is the Chief Medical Officer of Harpoon Therapeutics, a subsidiary of Merck & Co., Inc., Rahway, NJ, and brings nearly three decades of experience as a practicing oncologist and drug developer advancing new cancer therapies.

Zentalis Pharmaceuticals Announces Appointment of Accomplished Oncology Drug Developer Luke Walker, M.D., to Board of Directors

Administration of azenosertib combined with gemcitabine was well tolerated and resulted in clinically meaningful increase in event-free survival compared to historical comparators

Zentalis Pharmaceuticals to Present Promising Results from Phase 1 Trial of Azenosertib and Gemcitabine in Relapsed or Refractory Osteosarcoma at 2024 American Society of Clinical Oncology Annual Meeting

NEW YORK and SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that members of the management team will participate in a virtual fireside chat during the TD Cowen 5th Annual Oncology Innovation Summit: Insights for ASCO and EHA on May 28, 2024 at 10:30 a.m. ET.

Zentalis Pharmaceuticals to Present at TD Cowen 5th Annual Oncology Innovation Summit

Azenosertib clinical development plan on track with multiple data readouts in gynecological and other cancer types anticipated in the second half of 2024 and into 2025

Zentalis Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Progress

Zentalis Pharmaceuticals, Inc. expects final results from phase 1b study, using azenosertib + gemcitabine for the treatment of patients with osteosarcoma, in the 1st half of 2024. In a phase 1 study, using monotherapy azenosertib for 19 patients with platinum resistant or refractory ovarian cancer and uterine serous carcinoma patients, the ORR achieved was 37%. Initiation of a clinical trial using azenosertib for 1st-line maintenance platinum-sensitive ovarian cancer patients expected in 2025; Trial design to be revealed in the 2nd half of 2024.

Zentalis Pharmaceuticals: Data In 1st Half Of 2024 Could Get The Ball Rolling

Research supports azenosertib's potential to be highly synergistic in combination with KRAS targeted cancer therapeutics, creating an additional large opportunity to combine with other standard of care agents Research supports azenosertib's potential to be highly synergistic in combination with KRAS targeted cancer therapeutics, creating an additional large opportunity to combine with other standard of care agents

Zentalis Pharmaceuticals to Highlight Preclinical Data Demonstrating that WEE1 Inhibitor Azenosertib Exerts Synergistic Anti-tumor Activity with KRAS(G12C) Inhibitors at AACR Annual Meeting 2024

The consensus price target hints at a 136.4% upside potential for Zentalis Pharmaceuticals, Inc. (ZNTL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Think Zentalis Pharmaceuticals, Inc. (ZNTL) Could Surge 136.44%: Read This Before Placing a Bet

NEW YORK and SAN DIEGO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancer, today announced that Zentalis management will participate in several upcoming investor conferences:

Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences

Robust azenosertib clinical development plan ongoing and on track with multiple clinical catalysts anticipated, including monotherapy and combination data readouts in gynecological and other cancer types during 2024

Zentalis Pharmaceuticals Reports Full Year 2023 Financial Results and Operational Updates

Zentalis Pharmaceuticals, Inc. (ZNTL) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Down -19.06% in 4 Weeks, Here's Why You Should You Buy the Dip in Zentalis Pharmaceuticals, Inc. (ZNTL)

NEW YORK and SAN DIEGO, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancer, today announced that Kimberly Blackwell, M.D., Chief Executive Officer of Zentalis, will participate in a webcast fireside chat at the Oppenheimer Healthcare Life Sciences Conference on Wednesday, February 14, 2024 at 12:40 p.m. ET.

Zentalis Pharmaceuticals to Participate in the Oppenheimer Healthcare Life Sciences Conference

Zentalis Pharmaceuticals, Inc. (ZNTL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

What Makes Zentalis Pharmaceuticals, Inc. (ZNTL) a New Buy Stock

Zentalis Pharmaceuticals is positioned to become an oncology leader with its lead drug candidate, azenosertib, showing promising results in difficult-to-treat cancers. The company's financial health is strong, with a healthy cash reserve that will sustain operations until 2026. ZNTL is strategically expanding azenosertib's utility across wider indications and forming partnerships to reduce clinical trial risks and increase the likelihood of success.

Zentalis Pharmaceuticals: Azenosertib Continues To Impress

Diana Hausman, M.D., Accomplished Oncologist and Drug Developer, Appointed Chief Medical Officer Kyle Rasbach, Ph.D.

Zentalis Pharmaceuticals Strengthens Management Team with Key Appointments

LOS ANGELES, CA / ACCESSWIRE / January 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zentalis Pharmaceuticals, Inc. ("Zentalis" or "the Company") (NASDAQ:ZNTL) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

IMPORTANT INVESTOR ALERT: The Schall Law Firm Encourages Investors in Zentalis Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

Immunome

BOTHELL, Wash. & SAN DIEGO & NEW YORK--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM) and Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), today announced that they have entered into an exclusive, worldwide license agreement under which Immunome has licensed from Zentalis ZPC-21, a preclinical ROR1 antibody-drug conjugate (ADC) with best-in-class potential on track for IND submission in 1Q 2025, and Zentalis' proprietary ADC platform technology. “This agreement strengthens Immunome's pipeline wh.

News for Zentalis Pharmaceuticals Stock (ZNTL)